Similar to This
Lab Rats series: A Pune biotech startup’s new approach to vitiligo cure: Ahammune has advanced its first-in-class drug to solve vitiligo to mid-trials with a ...
livemint.com/companies/start-ups/lab-rats-series-a-pune-biotech-startup-s-new-approach-to-vitiligo-cure-11791867187983.html
Lab Rats series: A Pune biotech startup’s new approach to vitiligo cure
Roche continues to look to China for new drugs: Today's biotech news includes AltruBio's ulcerative colitis drug data, Merck to buy Silence ...
statnews.com/2026/10/20/biotech-news-roches-15b-hunt-for-new-drugs-in-china/
Roche continues to look to China for new drugs
FDA approves AstraZeneca breast cancer drug: Roivant drug delivers mid-stage results, Moonwalk raises funds to develop longer-lasting obesity drugs ...
statnews.com/2026/09/08/biotech-news-fda-approves-astrazeneca-breast-cancer-drug/
FDA approves AstraZeneca breast cancer drug
Hollie struggled to walk and was left fighting for her life with sepsis from ECZEMA… now new drug has ‘cured’ her
thesun.co.uk/health/39840179/hollie-eczema-sepsis-new-drug-cured-her-trial/
Hollie struggled to walk and was left fighting for her life with sepsis ...
Sanofi is scrapping its once-touted eczema drug in a new CEO pipeline overhaul: The French drugmaker said the drug would not represent a meaningful improvement ...
qz.com/sanofi-amlitelimab-eczema-drug-scrapped-ceo-pipeline-072426
Sanofi is scrapping its once-touted eczema drug in a new CEO pipeline ...
Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million: The deal focuses on Memo’s experimental drug potravitug, which is due to move to a mid- and ...
wsj.com/health/pharma/ipsen-to-buy-swiss-biotech-memo-in-deal-that-could-top-800-million-30979c46
Ipsen to Buy Swiss Biotech Memo in Deal That Could Top $800 Million
AbbVie would gain an experimental eczema drug by buying biotech: report: If approved, the drug would be a new option for people with atopic dermatitis
marketwatch.com/story/abbvie-would-gain-an-experimental-eczema-drug-by-buying-biotech-report-caf24728
AbbVie would gain an experimental eczema drug by buying biotech: report
Three cancer drugs and eczema medication approved for use by NHS Scotland: The Scottish Medicines Consortium said it had accepted five out of six newly-licensed ...
news.stv.tv/scotland/three-cancer-drugs-and-eczema-medication-approved-for-use-by-nhs-scotland
Three cancer drugs and eczema medication approved for use by NHS Scotland
Biogen lupus drug improves skin clearance in mid-stage study: Today's biotech news covers a positive mid-stage study for Biogen lupus drug ...
statnews.com/2026/03/30/biotech-news-biogen-lupus-drug-improves-skin-clearance-in-trial/
Biogen lupus drug improves skin clearance in mid-stage study
Apogee Therapeutics data show long-acting eczema drug induced relief with less frequent injections
statnews.com/2026/03/23/zumilokibart-apogee-eczema-clinical-trials-results/
Apogee Therapeutics data show long-acting eczema drug induced relief with ...
FDA rejection is a reality check on agency rhetoric : Today's biotech news covers Sarepta CEO Doug Ingram stepping down, the upcoming readout of ...
statnews.com/2026/02/26/biotech-news-fda-rejection-for-rare-blood-cancer-therapy/
FDA rejection is a reality check on agency rhetoric 
Investors cheer Compass’ psilocybin data  : Today's biotech news includes investors celebrating Compass' latest psilocybin data ...
statnews.com/2026/02/18/biotech-news-investors-celebrate-compass-psilocybin-data/
Investors cheer Compass’ psilocybin data  
Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson: Sanofi stock skidded Thursday after the pharma giant's board ousted Paul Hudson as CEO ...
investors.com/news/technology/sanofi-stock-paul-hudson-belen-garijo-ceo-transition/
Sanofi Tumbles After Board Shockingly Ousts CEO Paul Hudson
Eczema drug from Nektar Therapeutics maintains skin responses in one-year study: The results from Nektar’s maintenance study met and in some cases exceeded ...
statnews.com/2026/02/10/nektar-therapeutics-rezpeg-eczema-drug-maintains-skin-response-study/
Eczema drug from Nektar Therapeutics maintains skin responses in one-year ...
Hims faces mounting regulatory pressure: Today's biotech news covers ARPA-H cutting staff, Novo Nordisk's lawsuit against Hims ...
statnews.com/2026/02/09/biotech-news-novo-nordisk-sues-hims-patent-lawsuit/
Hims faces mounting regulatory pressure
IPOs, GLP-1s, and challenges with a gene therapy: Today's biotech news includes a heated rivalry between two eye drug companies, Novo and Hims facing off ...
statnews.com/2026/02/06/biotech-news-trumprx-launches-and-roivant-scores-a-win/
IPOs, GLP-1s, and challenges with a gene therapy
Pfizer defends data on Metsera candidate: Today's biotech news covers Novo seeing lower sales and profits this year, Pfizer defending data on Metsera ...
statnews.com/2026/02/04/biotech-news-pfizer-defends-metsera-data/
Pfizer defends data on Metsera candidate